Pfizer is reportedly weighing an attempt at an over-the-counter switch for Lipitor – a move that could help the company recoup some of its losses when the $11 billion drug loses nationwide exclusivity in November. But the reception from analysts has been muted so far. Pfizer is exploring the possibility of a branded generic, as well as an OTC switch, according to several sources.
